ArticleCancer medicine2025
GATA3 as a Prognostic Marker in Early-Stage Classical Mycosis Fungoides: Association With Disease Progression and Survival Outcomes.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides.The Journal of dermatology · 2026Article
- Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome.Frontiers in oncology · 2026Review
- GATA3 as a Prognostic Marker in Early-Stage Classical Mycosis Fungoides: Association With Disease Progression and Survival Outcomes.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectiveClassical mycosis fungoides (CMF), the most common form of primary cutaneous T-cell lymphoma, shows marked heterogeneity in disease progression and prognosis, while reliable molecular prognostic markers remain scarce. This study aimed to evaluate the prognostic significance of GATA-binding protein 3 (GATA3) expression in early-stage CMF.
methodsWe retrospectively analyzed 106 patients with early-stage CMF diagnosed at West China Hospital, Sichuan University, between 2009 and 2021. Immunohistochemistry (IHC) was performed to assess GATA3 expression in dermal tumor cells. Associations with progression-free survival (PFS) and overall survival (OS) were examined using Cox regression models adjusted by inverse probability of treatment weighting (IPTW). Receiver operating characteristic (ROC) curve analysis was conducted to evaluate predictive performance.
resultsHigh GATA3 expression (≥ 60%) was detected in 92.5% of cases. Elevated GATA3 levels were significantly associated with reduced PFS and OS. IPTW-adjusted Cox regression confirmed high GATA3 expression as an independent adverse prognostic factor. ROC curve analysis demonstrated strong predictive performance for CMF progression (AUC = 0.867), with an optimal cutoff of 57.5% (sensitivity 73.7%, specificity 94.3%). For clinical applicability, a 60% threshold was adopted.
conclusionHigh GATA3 expression is an independent adverse prognostic biomarker in early-stage CMF. Incorporating GATA3 into risk stratification models may improve prognostic accuracy and guide personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.